Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

93.600
+1.6501.79%
Volume:5.64M
Turnover:524.44M
Market Cap:160.43B
PE:-1.47K
High:94.300
Open:91.100
Low:90.650
Close:91.950
52wk High:109.100
52wk Low:28.650
Shares:1.71B
HK Float Shares:1.71B
Volume Ratio:1.23
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:2.65%
PB:10.16
PE(LYR):-1,470.03
PS:12.83

Loading ...

Innovent Biologics (SEHK:1801): Examining Valuation Following Significant Share Price Gains

Simply Wall St.
·
Oct 26

Zhao Yin International Raises Target Price for INNOVENT BIO (01801) to HKD 110.62 Following Strategic Partnership with Takeda Pharmaceutical Co Ltd

Stock News
·
Oct 24

Active Trading on Hong Kong Stock Connect | October 23

Stock News
·
Oct 23

Haitong International: Innovent Biologics (01801) and Takeda Pharmaceutical Co Ltd Reach $11.4 Billion Deal, Collaboration on Commercialization Looks Promising

Stock News
·
Oct 23

LCB: INNOVENT BIO (01801) and Takeda Pharmaceutical's Collaboration Positively Impacts Product Development, Target Price Raised to HKD 120.1

Stock News
·
Oct 23

Great Wall Pharmaceutical Industry Selected A Rises 15% in Q3, Increases Holdings in Innovent Bio and 3SBIO; Fund Manager Liang Furui: Current Innovative Drug Stocks Offer Great Value

Deep News
·
Oct 23

Bank of America Securities Raises Target Price for Innovent Biologics (01801) to HK$113, Collaboration with Takeda Marks Key Step in Becoming a Multinational Pharmaceutical Company

Stock News
·
Oct 23

CITIC Securities: Innovent Biologics (01801) Partners with Takeda for Global Strategic Cooperation, Maintains "Buy" Rating

Stock News
·
Oct 23

Innovent Biologics' Stunning BD Sparks Resurgence in Innovative Drug Initiatives

Deep News
·
Oct 23

Innovent Biologics, Inc.'s (HKG:1801) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Simply Wall St.
·
Oct 23

Hong Kong Stock Market Update | Innovent Bio and Takeda Pharmaceutical Reach Global Strategic Cooperation and Issue Shares Under General Authorization

Stock News
·
Oct 22

Muted Response to Innovent-Takeda Deal Could Be a Chance to Buy -- Market Talk

Dow Jones
·
Oct 22

China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion

Dow Jones
·
Oct 22

Nelson's $11.4 Billion BD Deal Validates Global Innovation and Commercialization Potential; INNOVENT BIO (01801) Valuation Outlook is Promising

Stock News
·
Oct 22

Innovent Biologics Sells License to Two Cancer Drugs to Takeda; Shares Up 3%

MT Newswires Live
·
Oct 22

Stock Track | Innovent Biologics Soars 9.90% on $11.4 Billion Cancer Therapy Deal with Takeda

Stock Track
·
Oct 22

BRIEF-Innovent Biologics Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Reuters
·
Oct 22

Shares of Innovent Biologics Set to Open up 9.9% on Cancer Therapy Deal With Japan's Takeda

THOMSON REUTERS
·
Oct 22

Innovent Biologics Secures Up to $11.4 Billion Global Collaboration Deal with Takeda

Reuters
·
Oct 22

Innovent Biologics Announces Global Strategic Partnership With Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

THOMSON REUTERS
·
Oct 22